loading page

The single-use fixed bed bioreactors in viral vector production
  • Hanna Lesch,
  • Piia Valonen,
  • Minna Karhinen
Hanna Lesch
Kuopio Center for Gene and Cell Therapy
Author Profile
Piia Valonen
Finvector
Author Profile
Minna Karhinen
Finvector
Author Profile

Abstract

The accelerating development of gene therapy from research towards clinical trials and beyond has elevated the demand for practical viral vector manufacturing solutions. The use of disposable upstream technology is gaining traction in clinical manufacturing. The world's first disposable, fully integrated, high-cell density fixed-bed bioreactor was launched approximately one decade ago. By now, the iCELLis fixed-bed technology has obtained the broadest customer base. This system is available in small scale but also provides the largest GMP compliant commercial system. However, there are several alternative technologies, which have been widely used for the manufacturing of different viral vectors, allowing for complementation within the market. This article will review virus production using the latest disposable fixed-bed bioreactors, present highlights of an interview with the inventor of these bioreactors, and share some user experience. It is predicted that single-use fixed-bed bioreactors will receive even more attention in the field of viral vector manufacturing and commercialization, especially with high virus yields.

Peer review status:ACCEPTED

13 May 2020Submitted to Biotechnology Journal
18 May 2020Submission Checks Completed
18 May 2020Assigned to Editor
18 May 2020Reviewer(s) Assigned
02 Jul 2020Editorial Decision: Revise Major
16 Jul 20201st Revision Received
20 Jul 2020Assigned to Editor
20 Jul 2020Submission Checks Completed
20 Jul 2020Reviewer(s) Assigned
03 Sep 2020Editorial Decision: Revise Minor
04 Sep 20202nd Revision Received
05 Sep 2020Assigned to Editor
05 Sep 2020Reviewer(s) Assigned
05 Sep 2020Submission Checks Completed
05 Sep 2020Editorial Decision: Accept